Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy.
作者信息
Demissei Biniyam G, Finkelman Brian S, Hubbard Rebecca A, Smith Amanda M, Narayan Hari K, Narayan Vivek, Shah Payal, Waxman Adam J, Domchek Susan M, Ky Bonnie
出版信息
J Am Coll Cardiol. 2019 Jan 22;73(2):248-249. doi: 10.1016/j.jacc.2018.10.057.
Abstract
摘要
相似文献
1
Cardiovascular Function Phenotypes in Response to Cardiotoxic Breast Cancer Therapy.乳腺癌心脏毒性治疗后的心血管功能表型
J Am Coll Cardiol. 2019 Jan 22;73(2):248-249. doi: 10.1016/j.jacc.2018.10.057.
2
Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.超重对蒽环类药物和曲妥珠单抗在乳腺癌中所致心脏毒性的影响。
Arch Cardiovasc Dis. 2017 Feb;110(2):69-71. doi: 10.1016/j.acvd.2016.12.004. Epub 2017 Feb 16.
3
Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer.蒽环类药物和曲妥珠单抗引起的乳腺癌心脏毒性。
Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2175-2185. doi: 10.26355/eurrev_201804_14752.
4
Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity.心血管危险因素与蒽环类药物和曲妥珠单抗心脏毒性的发生时间
Anticancer Res. 2019 Oct;39(10):5741-5745. doi: 10.21873/anticanres.13775.
5
Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.靶向癌症药物的心脏毒性：关注、“本末倒置”以及曲妥珠单抗的教训。
Curr Cardiol Rep. 2019 Mar 18;21(5):33. doi: 10.1007/s11886-019-1121-0.
6
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.曲妥珠单抗皮下制剂治疗人表皮生长因子受体 2 阳性早期或局部晚期乳腺癌患者的安全性特征：SCHEARLY 研究的主要分析。
Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3.
7
Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.治疗洞察：蒽环类药物与曲妥珠单抗——心脏毒性副作用的最佳管理
Nat Clin Pract Oncol. 2008 Jun;5(6):324-35. doi: 10.1038/ncponc1090. Epub 2008 Mar 25.
8
Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.曲妥珠单抗治疗 HER2 阳性乳腺癌患者的他汀类药物的心脏保护作用。
Can J Cardiol. 2019 Feb;35(2):153-159. doi: 10.1016/j.cjca.2018.11.028. Epub 2018 Dec 4.
9
Excess heart age in young breast cancer survivors over 2-year follow-up.年轻乳腺癌幸存者随访 2 年以上的心脏年龄偏高。
Cancer Causes Control. 2021 Jun;32(6):617-626. doi: 10.1007/s10552-021-01415-3. Epub 2021 Mar 24.
10
Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.早期乳腺癌中体质量指数与蒽环类药物和曲妥珠单抗相关心脏毒性的关系：法国 CANTO 队列研究。
PLoS Med. 2019 Dec 23;16(12):e1002989. doi: 10.1371/journal.pmed.1002989. eCollection 2019 Dec.
引用本文的文献
1
Prediction of Radiation Therapy Induced Cardiovascular Toxicity from Pretreatment CT Images in Patients with Thoracic Malignancy via an Optimal Biomarker Approach.通过优化生物标志物方法，利用胸部恶性肿瘤患者治疗前CT图像预测放射治疗诱发的心血管毒性
Acad Radiol. 2025 Apr;32(4):1895-1905. doi: 10.1016/j.acra.2025.01.012. Epub 2025 Jan 26.
2
Oncologist phenotypes and associations with response to a machine learning-based intervention to increase advance care planning: Secondary analysis of a randomized clinical trial.肿瘤学家表型与基于机器学习的干预措施反应的关联，以增加预先护理计划：一项随机临床试验的二次分析。
PLoS One. 2022 May 27;17(5):e0267012. doi: 10.1371/journal.pone.0267012. eCollection 2022.
3
The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment.曲妥珠单抗诱导的心脏毒性在HER-2阳性乳腺癌治疗中的研究进展
Front Cardiovasc Med. 2022 Jan 12;8:821663. doi: 10.3389/fcvm.2021.821663. eCollection 2021.
4
Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology.全球心脏肿瘤学峰会会议记录：心脏肿瘤学需落实的十大优先事项
JACC CardioOncol. 2019 Dec 17;1(2):256-272. doi: 10.1016/j.jaccao.2019.11.007. eCollection 2019 Dec.
5
Phenotyping physician practice patterns and associations with response to a nudge in the electronic health record for influenza vaccination: A quasi-experimental study.在电子健康记录中对流感疫苗接种进行“轻推”，以表型医生的实践模式及其与反应的关联：一项准实验研究。
PLoS One. 2020 May 20;15(5):e0232895. doi: 10.1371/journal.pone.0232895. eCollection 2020.
6
Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy.详细的表型分析揭示了现代乳腺癌治疗暴露下心血管功能和症状的不同轨迹。
Cancer. 2019 Aug 15;125(16):2762-2771. doi: 10.1002/cncr.32149. Epub 2019 May 1.
本文引用的文献
1
Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.乳腺癌患者的详细超声心动图表型分析：与3年随访期间射血分数下降、恢复及心力衰竭症状的关联
Circulation. 2017 Apr 11;135(15):1397-1412. doi: 10.1161/CIRCULATIONAHA.116.023463. Epub 2017 Jan 19.
2
A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.个性化 BEST：非缺血性心力衰竭潜在临床亚组的特征可预测预后和对布新洛尔的反应。
PLoS One. 2012;7(11):e48184. doi: 10.1371/journal.pone.0048184. Epub 2012 Nov 7.
3
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.蒽环类和曲妥珠单抗治疗后乳腺癌患者心力衰竭的风险：一项回顾性队列研究。
J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.
4
Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes.整合以人为主和以变量为主的分析：具有潜在轨迹类别的增长混合模型
Alcohol Clin Exp Res. 2000 Jun;24(6):882-91.
Zotero 插件